Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)

[Image: see text] Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients. In particular, IDO1 inhibition is of int...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Med Chem Lett
Autors principals: White, Catherine, McGowan, Meredeth A., Zhou, Hua, Sciammetta, Nunzio, Fradera, Xavier, Lim, Jongwon, Joshi, Elizabeth M., Andrews, Christine, Nickbarg, Elliott B., Cowley, Phillip, Trewick, Sarah, Augustin, Martin, von Köenig, Konstanze, Lesburg, Charles A., Otte, Karin, Knemeyer, Ian, Woo, Hyun, Yu, Wensheng, Cheng, Mangeng, Spacciapoli, Peter, Geda, Prasanthi, Song, Xuelei, Smotrov, Nadya, Curran, Patrick, Heo, Mee Ra, Abeywickrema, Pravien, Miller, J. Richard, Bennett, David Jonathan, Han, Yongxin
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2020
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7153270/
https://ncbi.nlm.nih.gov/pubmed/32292563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.0c00010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars